Praful Bohra of Religare is confident of the company clocking EBITDA margins of around 20.7 percent for FY16 and a similar number for FY17 too. Money Control, 2 months ago
The government over the weekend banned 344 Fixed Dose Combinations (FDCs) drugs, which will impact nearly 4-5 percent of the Indian pharmaceutical industry. Kewal Handa, industry expert and former MD of Pfizer says that alongwith sales loss, ...Moneycontrol.com, 1 month ago
on your WebpageAdd Widget >Get your members hooked!